Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C68H105N11O15 |
| Molecular Weight | 1316.626 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 12 / 12 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@]([C@@H](C)CC)([C@@H](CC(=O)N1CCC[C@@]1([H])[C@H](OC)[C@@H](C)C(=O)N[C@H](C)[C@@H](O)C2=CC=CC=C2)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C(=O)OCC3=CC=C(NC(=O)[C@H](CCCNC(N)=O)NC(=O)[C@@H](NC(=O)CCCCCN4C(=O)C=CC4=O)C(C)C)C=C3)C(C)C
InChI
InChIKey=NLMBVBUNULOTNS-HOKPPMCLSA-N
InChI=1S/C68H105N11O15/c1-15-43(8)59(51(92-13)38-55(83)78-37-23-27-50(78)61(93-14)44(9)62(85)71-45(10)60(84)47-24-18-16-19-25-47)76(11)66(89)57(41(4)5)75-65(88)58(42(6)7)77(12)68(91)94-39-46-29-31-48(32-30-46)72-63(86)49(26-22-35-70-67(69)90)73-64(87)56(40(2)3)74-52(80)28-20-17-21-36-79-53(81)33-34-54(79)82/h16,18-19,24-25,29-34,40-45,49-51,56-61,84H,15,17,20-23,26-28,35-39H2,1-14H3,(H,71,85)(H,72,86)(H,73,87)(H,74,80)(H,75,88)(H3,69,70,90)/t43-,44+,45+,49-,50-,51+,56-,57-,58-,59-,60+,61+/m0/s1
| Molecular Formula | C68H105N11O15 |
| Molecular Weight | 1316.626 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 12 / 12 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
VcMMAE (valine-citrulline-MMAE) is a drug-linker conjugate for antibody-drug conjugates (ADC) with potent antitumor activity by using the anti-mitotic and cytotoxic drug, monomethyl auristatin E (MMAE). MMAE is linked via the lysosomally cleavable dipeptide, valine-citrulline (vc), which can be specifically hydrolyzed by endosomal proteases, such as cathepsin B. ADCs developed using the valine-citrulline-MMAE (vc-MMAE) platform are studied for the treatment of different types of cancers.
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Physiologically based pharmacokinetic modeling as a tool to predict drug interactions for antibody-drug conjugates. | 2015 Jan |
|
| Design and characteristics of cytotoxic fibroblast growth factor 1 conjugate for fibroblast growth factor receptor-targeted cancer therapy. | 2016 |
|
| Platform model describing pharmacokinetic properties of vc-MMAE antibody-drug conjugates. | 2017 Dec |
Sample Use Guides
It was evaluated the cytotoxic effect of the FGF1V–vcMMAE conjugate on FGFR-expressing cells, including a model human fibroblast cell line, BJ. To test whether the cytotoxic effect is specific to FGFR-expressing cells, we employed a model system of U2OS and U2OS FGFR1 cells (stably transfected with the FGFR1) in which otherwise identical osteosarcoma cells lacking and expressing FGFRs can be compared. All the cell lines were treated with increasing concentrations (1*10(-9) – 1*10(-5) M) of the conjugate, FGF1V, or vcMMAE for 96 hours, and then their viability was assessed by the alamarBlue assay or counting in trypan Blue stain. As the maximum cytotoxic effect of both vcMMAE and FGF1V–MMAE was reached after 72–96 hours, the cytotoxicity assessment was performed after 96 hours of treatment.
| Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 05:44:33 UTC 2023
by
admin
on
Sat Dec 16 05:44:33 UTC 2023
|
| Record UNII |
026S2O80A8
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
646502-53-6
Created by
admin on Sat Dec 16 05:44:33 UTC 2023 , Edited by admin on Sat Dec 16 05:44:33 UTC 2023
|
PRIMARY | |||
|
46944733
Created by
admin on Sat Dec 16 05:44:33 UTC 2023 , Edited by admin on Sat Dec 16 05:44:33 UTC 2023
|
PRIMARY | |||
|
026S2O80A8
Created by
admin on Sat Dec 16 05:44:33 UTC 2023 , Edited by admin on Sat Dec 16 05:44:33 UTC 2023
|
PRIMARY |